Mosapride
From Wikipedia, the free encyclopedia
Mosapride
|
|
Systematic (IUPAC) name | |
4-amino-5-chloro-2-ethoxy-N-[(4-[(4-fluorophenyl)methyl]morpholin-2-yl)methyl]benzamide | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C21H25ClFN3O3 |
Mol. mass | 421.893 g/mol |
Synonyms | Mosapride |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Mosapride is a selective 5HT4 agonist[1] which accelerates gastric emptying and is used for the treatment of acid reflux[2], irritable bowel syndrome and functional dyspepsia.[3]
[edit] References
- ^ Kato S, Morie T, Yoshida N. Synthesis and biological activities of metabolites of mosapride, a new gastroprokinetic agent. Chemical and Pharmaceutical Bulletin (Tokyo). 1995 Apr;43(4):699-702.
- ^ Ruth M, Hamelin B, Rohss K, Lundell L. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics. 1998 Jan;12(1):35-40.
- ^ Mizuta Y, Shikuwa S, Isomoto H, Mishima R, Akazawa Y, Masuda J, Omagari K, Takeshima F, Kohno S. Recent insights into digestive motility in functional dyspepsia. Journal of Gastroenterology. 2006 Nov;41(11):1025-40.
|